CDEX Secures Order for 10 Units of its ValiMed CCT System

December 12, 2012, by , Posted in Press Releases, Comments Off on CDEX Secures Order for 10 Units of its ValiMed CCT System

TUCSON, AZ–(December 12, 2012) – CDEX Inc. (OTC.QB:CDEX), a leading developer of chemical
detection products using patented technologies for use in healthcare, safety and security markets, today
announced the company secured an order for 10 units of its ValiMed™ CCT drug validation system from
Al-Essa Medical & Scientific Equipment Company in Safat, Kuwait. The company expects to deliver the
units with testing supplies and signatures in the first quarter 2013. The initial sales agreement calls for
additional fees for installation of the CCT units and product support for two years from the date of
CDEX received the initial deposit of one hundred and ninety nine thousand dollars for the ten ValiMed
machines, which enabled the company to begin the procurement of materials and initiate final assembly
of the units. CDEX is contracted to deliver the units in the first quarter of 2013 and will receive the final
payment balance of the order within thirty days after shipment. The company will provide the initial
training and support to Al-Essa’s technical staff, and once both parties are satisfied with the competency
and abilities of the Al-Essa trainers, they will then take full responsibilities for installation and training
for their clients.

“We are very pleased to secure the single largest international order for our ValiMed systems in the
company’s history. We anticipate future sales for supplies and service related to the initial sale of these
units. With this order, the Al-Essa Group and CDEX Inc. have entered into an agency relationship which
allows CDEX Inc. access to markets in the Middle East that otherwise would not be possible. The
ValiMed systems will reinforce their client’s efforts to fight narcotics diversion in the healthcare systems
they serve,” stated Jeff Brumfield, chairman and chief executive officer of CDEX.
The ValiMed™ Medication Validation and Narcotics Return System (Model CCT), is a lightweight,
compact table top instrument that can be used in virtually any clinical environment where high-risk IV
medications are compounded before being dispensed to the patient, or where narcotics are returned
after being dispensed. CDEX’s ValiMed drug validation technology helps healthcare providers ensure
patient safety and control costs by reducing medication errors and mitigating drug diversion. The
patented & patent pending detection process identifies drugs in real-time, validating medication and
treatment solutions authenticity and specificity.


About Al-Essa Group

For over 30 years, professionals in healthcare, analytical and various other industries have experienced
Al-Essa’s proven commitment to deliver total solutions to clients in both private and public institutions,
in Kuwait and GCC. With a long and proven experience in introducing cutting-edge healthcare and
analytical equipment from world-class manufacturers, their activities range from supplying products, supporting applications and providing maintenance for medical and analytical needs, address human
resource requirements through supplemental staffing and home healthcare programs, and deliver
complete solutions in facility engineering. To date, Al-Essa has executed several projects on a turnkey
basis by combining local project management and project support expertise with international
technology partners. For more information visit


About CDEX Inc.

CDEX develops, manufactures and globally distributes products to the healthcare, safety and security
markets. The ValiMed™ product line provides life-saving validation of high-risk medications and
pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as
methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in
the future where its proprietary products can be launched. To learn more about CDEX please
visit: .
Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can
be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar
words. These statements pose risks that cannot be accurately predicted. Consequently, results may
differ materially from those expressed or implied. Such risks and uncertainties include, without
limitation, the effectiveness, profitability and marketability of products, the protection of intellectual
property and proprietary information, and other risks detailed periodically in filings with the SEC. There
is no obligation to update any forward-looking statements.
Company contact:
Jeff Brumfield
Chairman and CEO